Protara Therapeutics, Inc.
NASDAQ:TARABiotechnology
-$0.05 today
- Market cap
- $144.07M
- Beta
- 1.45
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$1.48
Volume 1.15M
Average 0.73M
TARA Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Protara Therapeutics, Inc.NASDAQ: TARA
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents falls 83.9% from a year ago
Cash & equivalents stood at $14.74M at the end of Q1 FY2026, down 83.9% from a year earlier and down 70.3% from the prior quarter. Over 3 fiscal years it compounded at +27.2% a year.
Context
- Cash & equivalents amounted to 7.7% of total assets at the end of Q1 FY2026, down 46.6 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -83.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 49.66M USD
- Year-over-year change
- -69.5%
- 4-year CAGR
- +8.6%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 49.66M | -69.5% |
| FY2024 | 2024-12-31 | 162.8M | +311.3% |
| FY2023 | 2023-12-31 | 39.59M | +64.1% |
| FY2022 | 2022-12-31 | 24.13M | -32.5% |
| FY2021 | 2021-12-31 | 35.72M | — |
Cash & Equivalents vs competitors
How TARA compares with its peers on the latest reported figures
- TARA's Mar 2026 cash & equivalents of $14.74M is the 9th highest of the 10 companies compared; the peer median is $29.05M.
- Its year-over-year change of -83.9% is the 9th highest of 10, against a peer median of +54.6%.
- Cash & equivalents amounts to 7.7% of total assets for TARA, versus a peer median of 28.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $184.15M | +283.0% | +35.0% | 76.2% | |
| Sep 2026 | $134.71M | +203.3% | +61.3% | 95.5% | |
| Mar 2026 | $44.65M | +16.7% | -47.9% | 55.8% | |
| Mar 2026 | $37M | +102.0% | -23.6% | 28.6% | |
| Mar 2026 | $29.05M | +166.7% | -8.6% | 9.9% | |
| Mar 2026 | $28.37M | +54.6% | +20.6% | 28.2% | |
| Mar 2026 | $27.59M | +9.6% | -40.7% | 46.0% | |
| Mar 2026 | $21.76M | -46.0% | +4.8% | 18.2% | |
| Mar 2026 | $14.74M | -83.9% | +27.2% | 7.7% | |
| Mar 2026 | $138.6K | -97.5% | — | 4.2% | |
| Peer median (excluding TARA) | $29.05M | +54.6% | -1.9% | 28.6% | |
Competitors are the stored peer set for TARA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 35.72M | 24.13M | 39.59M | 162.8M | 49.66M |
| Short-term Investments | 55.51M | 60.24M | 25.99M | 7.49M | 105.9M |
| Net Receivables | 634K | 486K | 242K | 0 | 1.26M |
| Inventory | 0 | 1.16M | 0 | 0 | 0 |
| Other Current Assets | 34K | (1.04M) | 37K | 2K | 65K |
| Total Current Assets | 93.11M | 86.15M | 68.71M | 172.16M | 159.5M |
| Property, Plant & Equipment (Net) | 8.89M | 7.87M | 6.56M | 5.28M | 3.93M |
| Goodwill | 29.52M | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 84K | 2.66M | 3.25M | 2.93M |
| Long-term Investments | 39.47M | 17.89M | 0 | 0 | 42.34M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.61M | 1.31M | 1.03M | 772K | 765K |
| Total Non-current Assets | 79.48M | 27.14M | 10.25M | 9.3M | 49.96M |
| Total Assets | 172.6M | 113.29M | 78.95M | 181.45M | 209.47M |
| Account Payables | 954K | 1.59M | 2.43M | 4.43M | 3.47M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 41K | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.8M | 2.54M | 2.11M | 2.53M | 3.27M |
| Total Current Liabilities | 4.3M | 5.74M | 6.15M | 10.96M | 10.94M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 6.38M | 5.47M | 4.48M | 3.36M | 2.12M |
| Total Liabilities | 10.68M | 11.21M | 10.63M | 14.32M | 13.06M |
| Common Stock | 11K | 11K | 11K | 35K | 54K |
| Retained Earnings | (94.01M) | (159.96M) | (200.38M) | (244.98M) | (302.42M) |
| Accumulated OCI | (211K) | (688K) | (31K) | 2K | 90K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 161.91M | 102.08M | 68.32M | 167.13M | 196.41M |
| Total Debt | 7.24M | 6.38M | 5.47M | 4.48M | 3.36M |
| Net Debt | (28.49M) | (17.74M) | (34.12M) | (158.32M) | (46.3M) |
Protara Therapeutics, Inc.
NASDAQ:TARA
Intrinsic Alpha fair value
Locked
Current Price
$2.34
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.